130 related articles for article (PubMed ID: 16790517)
1. Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group.
Fountzilas G; Papakostas P; Dafni U; Makatsoris T; Karina M; Kalogera-Fountzila A; Maniadakis N; Aravantinos G; Syrigos K; Bamias A; Christodoulou C; Economopoulos T; Kalofonos H; Nikolaou A; Angouridakis N; Stathopoulos G; Bafaloukos D; Pavlidis N; Daniilidis J
Ann Oncol; 2006 Oct; 17(10):1560-7. PubMed ID: 16790517
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group.
Fountzilas G; Stathopoulos G; Nicolaides C; Kalogera-Fountzila A; Kalofonos H; Nikolaou A; Bacoyiannis C; Samantas E; Papadimitriou C; Kosmidis P; Daniilidis J; Pavlidis N
Ann Oncol; 1999 Apr; 10(4):475-8. PubMed ID: 10370793
[TBL] [Abstract][Full Text] [Related]
3. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Edwards SJ; Barton S; Thurgar E; Trevor N
Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
[TBL] [Abstract][Full Text] [Related]
4. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W
Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470
[TBL] [Abstract][Full Text] [Related]
5. Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
Janinis J; Stathopoulos GP; Nikolaidis P; Kalofonos HP; Kalogera-Fountzila A; Samantas E; Aravantinos G; Anagnostopoulos A; Tolis C; Makatsoris T; Rigatos SK; Bafaloukos D; Dimopoulos MA; Daniilidis J; Fountzilas G
Anticancer Drugs; 2004 Jun; 15(5):479-87. PubMed ID: 15166622
[TBL] [Abstract][Full Text] [Related]
6. A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer.
Tas F; Guney N; Derin D; Aydiner A; Topuz E
Int J Clin Oncol; 2008 Apr; 13(2):156-60. PubMed ID: 18463961
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study.
Bafaloukos D; Linardou H; Aravantinos G; Papadimitriou C; Bamias A; Fountzilas G; Kalofonos HP; Kosmidis P; Timotheadou E; Makatsoris T; Samantas E; Briasoulis E; Christodoulou C; Papakostas P; Pectasides D; Dimopoulos AM
BMC Med; 2010 Jan; 8():3. PubMed ID: 20055981
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J; Shannon CM; Baumann K; Rau J; Harter P; Joly F; Sehouli J; Canzler U; Schmalfeldt B; Dean AP; Hein A; Zeimet AG; Hanker LC; Petit T; Marmé F; El-Balat A; Glasspool R; de Gregorio N; Mahner S; Meniawy TM; Park-Simon TW; Mouret-Reynier MA; Costan C; Meier W; Reinthaller A; Goh JC; L'Haridon T; Baron Hay S; Kommoss S; du Bois A; Kurtz JE;
Lancet Oncol; 2020 May; 21(5):699-709. PubMed ID: 32305099
[TBL] [Abstract][Full Text] [Related]
9. Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma.
Poh SB; Bai LY; Chen PM
Am J Clin Oncol; 2005 Dec; 28(6):540-6. PubMed ID: 16317261
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG).
Kosmidis PA; Fountzilas G; Eleftheraki AG; Kalofonos HP; Pentheroudakis G; Skarlos D; Dimopoulos MA; Bafaloukos D; Pectasides D; Samantas E; Boukovinas J; Lambaki S; Katirtzoglou N; Bakogiannis C; Syrigos KN
Ann Oncol; 2011 Apr; 22(4):827-834. PubMed ID: 20880999
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
Fountzilas G; Christodoulou C; Tsavdaridis D; Kalogera-Fountzila A; Aravantinos G; Razis E; Kalofonos HP; Papakostas P; Karina M; Gogas H; Skarlos D
Cancer Invest; 2004; 22(5):655-62. PubMed ID: 15581045
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine and paclitaxel in metastatic or recurrent squamous cell carcinoma of the head and neck: a phase I-II study.
Stier S; Koll C; Neuhaus T; Fronhoffs S; Forkert R; Tuohimaa A; Vetter H; Ko Y
Anticancer Drugs; 2005 Nov; 16(10):1115-21. PubMed ID: 16222154
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of pegylated liposomal doxorubicin (Caelyx) plus Gemcitabine in chemotherapeutically pretreated patients with advanced breast cancer.
Ulrich-Pur H; Kornek GV; Haider K; Kwasny W; Payrits T; Dworan N; Vormittag L; Depisch D; Lang F; Scheithauer W
Acta Oncol; 2007; 46(2):208-13. PubMed ID: 17453371
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329.
Malhotra B; Moon J; Kucuk O; Clark JI; Urba SG; Wolf GT; Worden FP
Head Neck; 2014 Dec; 36(12):1712-7. PubMed ID: 24166832
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma.
Pectasides D; Xiros N; Papaxoinis G; Aravantinos G; Sykiotis C; Pectasides E; Psyrri A; Koumarianou A; Gaglia A; Gouveris P; Economopoulos T
Gynecol Oncol; 2008 Jan; 108(1):47-52. PubMed ID: 17915300
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin.
Mirza MR; Lund B; Lindegaard JC; Keldsen N; Mellemgaard A; Christensen RD; Bertelsen K
Gynecol Oncol; 2010 Oct; 119(1):26-31. PubMed ID: 20638711
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.
Sánchez-Rovira P; Jaén A; González E; Porras I; Dueñas MR; Medina B; Mohedano N; Fernández M; Martos M; Lozano A
Clin Breast Cancer; 2000 Oct; 1(3):226-32. PubMed ID: 11899647
[TBL] [Abstract][Full Text] [Related]
18. Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel - pretreated ovarian carcinoma.
Pectasides D; Pectasides E; Papaxoinis G; Psyrri A; Pliarchopoulou K; Koumarianou A; Macheras A; Athanasas G; Xiros N; Economopoulos T
Gynecol Oncol; 2010 Jul; 118(1):52-7. PubMed ID: 20406710
[TBL] [Abstract][Full Text] [Related]
19. The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer.
Giuliani J; Bonetti A
Int J Gynecol Cancer; 2017 Nov; 27(9):1872-1876. PubMed ID: 28976446
[TBL] [Abstract][Full Text] [Related]
20. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S
Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
